NO960837L - Nye kuler for regulert frigjöring og et farmasöytisk preparat inneholdende slike - Google Patents

Nye kuler for regulert frigjöring og et farmasöytisk preparat inneholdende slike

Info

Publication number
NO960837L
NO960837L NO960837A NO960837A NO960837L NO 960837 L NO960837 L NO 960837L NO 960837 A NO960837 A NO 960837A NO 960837 A NO960837 A NO 960837A NO 960837 L NO960837 L NO 960837L
Authority
NO
Norway
Prior art keywords
controlled release
pharmaceutical preparation
preparation containing
new balls
balls
Prior art date
Application number
NO960837A
Other languages
English (en)
Other versions
NO960837D0 (no
Inventor
Lars Stubberud
Hans Arwidsson
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of NO960837L publication Critical patent/NO960837L/no
Publication of NO960837D0 publication Critical patent/NO960837D0/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Abstract

Kuler med regulert frigjøringsvirkning inneholdende en kjerne omkring hvilken det befinner seg et legemiddelholdig lag, f.eks et lag inneholdende furosemid, og en frem- gangsmåte for deres fremstilling og deres anvendelse i et farmasøytisk preparat. Kulene med regulert frigjøringsvirkning har utmerkede mekaniske og frigjørende egenskaper.
NO960837A 1994-07-08 1996-02-29 Nye kuler for regulert frigjöring og et farmasöytisk preparat inneholdende slike NO960837D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402422A SE9402422D0 (sv) 1994-07-08 1994-07-08 New beads for controlled release and a pharmaceutical preparation containing the same
PCT/SE1995/000676 WO1996001621A1 (en) 1994-07-08 1995-06-07 New beads for controlled release and a pharmaceutical preparation containing the same

Publications (2)

Publication Number Publication Date
NO960837L true NO960837L (no) 1996-02-29
NO960837D0 NO960837D0 (no) 1996-02-29

Family

ID=20394677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960837A NO960837D0 (no) 1994-07-08 1996-02-29 Nye kuler for regulert frigjöring og et farmasöytisk preparat inneholdende slike

Country Status (23)

Country Link
US (1) US5783215A (no)
EP (1) EP0723434A1 (no)
JP (1) JPH09502738A (no)
CN (1) CN1134108A (no)
AU (1) AU700949B2 (no)
BR (1) BR9506026A (no)
CA (1) CA2170526A1 (no)
CZ (1) CZ73196A3 (no)
EE (1) EE03280B1 (no)
FI (1) FI961056A (no)
HU (1) HUT75772A (no)
IL (1) IL114448A (no)
MX (1) MX9600858A (no)
NO (1) NO960837D0 (no)
NZ (1) NZ289947A (no)
PL (1) PL313386A1 (no)
RU (1) RU2141822C1 (no)
SE (1) SE9402422D0 (no)
SK (1) SK30396A3 (no)
TR (1) TR199500822A2 (no)
TW (1) TW460300B (no)
WO (1) WO1996001621A1 (no)
ZA (1) ZA955545B (no)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2758461A1 (fr) * 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
CO5070568A1 (es) 1998-05-22 2001-08-28 Eurand Internatrional Spa Proceso de aplicacion de capas y aparato para efectuarlo
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
DE19842753A1 (de) * 1998-09-18 2000-03-23 Bayer Ag Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
SK6412002A3 (en) 1999-11-11 2002-09-10 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
WO2003013609A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
MXPA04006163A (es) * 2001-12-20 2004-11-01 Pharmacia Corp Formas de dosis de liberacion sostenida del orden-cero y metodo de fabricacion de las mismas.
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
CO5400144A1 (es) 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
AU2003236947A1 (en) * 2002-06-07 2003-12-22 Ranbaxy Laboratories Limited Modified release, multiple unit drug delivery systems
US7803402B2 (en) * 2002-07-06 2010-09-28 Sanjeev Khandelwal Pharmaceutical preparations
FR2842736B1 (fr) * 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
CA2515130A1 (en) 2003-02-05 2004-08-26 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
WO2004105735A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
US20070224269A1 (en) * 2004-06-10 2007-09-27 Rubino Orapin P Controlled Release Pharmaceutical Formulation
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
SI1915137T1 (sl) 2005-08-10 2013-12-31 Add Advanced Drug Delivery Technologies, Ltd. Pripravek z nadzorovanim sproščanjem za peroralno dajanje
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
DK1993559T3 (en) 2006-02-03 2016-10-03 Opko Renal Llc Treatment of vitamin D deficiency and MALFUNCTION with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
WO2007097770A1 (en) * 2006-02-24 2007-08-30 Teva Pharmaceutical Industries Ltd. Metoprolol succinate e.r. tablets and methods for their preparation
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
EP2012756A4 (en) * 2006-04-20 2013-01-23 Inventia Healthcare Private Ltd MULTI-UNIT COMPOSITIONS
WO2007122015A1 (en) * 2006-04-21 2007-11-01 Synthon B.V. Tolterodine beads
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
SI2037936T1 (sl) 2006-06-21 2014-11-28 Opko Renal, Llc Postopek zdravljenja in prepreäśevanja sekundarnega hiperparatiroidizma
WO2008014175A2 (en) * 2006-07-28 2008-01-31 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
CA2683514C (en) 2007-04-25 2019-07-09 Proventiv Therapeutics, Llc Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
KR20190141269A (ko) 2007-04-25 2019-12-23 사이토크로마 인코포레이티드 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
WO2009003724A1 (en) * 2007-07-03 2009-01-08 Synthon B.V. Tolterodine bead
CA2629099A1 (en) * 2008-04-01 2009-10-01 Pharmascience Inc. Novel oral controlled release pharmaceutical formulations
CN106853250A (zh) 2008-04-02 2017-06-16 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
JP2012500823A (ja) * 2008-08-29 2012-01-12 グラクソ グループ リミテッド 1−イソプロピル−4−{[4−(テトラヒドロ−2h−ピラン−4−イルオキシ)フェニル]カルボニル}ヘキサヒドロ−1h−1,4−ジアゼピンまたはその塩を含んでなる剤形
US20140112995A1 (en) * 2009-07-31 2014-04-24 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
EP2459180A1 (en) 2009-07-31 2012-06-06 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
RS60087B1 (sr) 2010-03-29 2020-05-29 Opko Ireland Global Holdings Ltd Postupci i kompozicije za snižavanje nivoa paratireoidnog hormona
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
AU2014246617A1 (en) 2013-12-23 2015-07-09 Sun Pharmaceutical Industries Limited Multi-layered, multiple unit pharmaceutical compositions
CN114681468A (zh) 2014-08-07 2022-07-01 欧普科爱尔兰环球控股有限公司 利用25-羟基维生素d的辅助疗法
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
MX2018008004A (es) * 2015-12-28 2019-03-28 Ssp Co Ltd Japan Preparacion farmaceutica compactada.
IL243707A0 (en) 2016-01-20 2016-05-01 Galmed Res And Dev Ltd Treatment to regulate the microbiota in the intestine
CN108883120A (zh) 2016-03-28 2018-11-23 欧普科爱尔兰环球控股有限公司 维生素d治疗方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN108272766B (zh) * 2018-03-21 2020-07-07 江苏四环生物制药有限公司 一种甲钴胺分散迟释片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4716041A (en) * 1984-02-10 1987-12-29 A/S Alfred Benzon Diffusion coated multiple-units dosage form
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
FR2610327B1 (fr) * 1987-01-30 1989-08-25 Charbonnages Ste Chimique Interpolymere composite a plusieurs couches, son procede de preparation, son application au renforcement de matrices thermoplastiques rigides et compositions renforcees correspondantes
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
CA1338596C (en) * 1988-09-27 1996-09-17 Hiroyoshi Koyama Granules having core and their production
US5084287A (en) * 1990-03-15 1992-01-28 Warner-Lambert Company Pharmaceutically useful micropellets with a drug-coated core and controlled-release polymeric coat
EP0447168A3 (en) * 1990-03-16 1993-01-07 Yamanouchi Pharmaceutical Co. Ltd. Long acting granular pharmaceutical composition
EP0452862B1 (en) * 1990-04-18 1995-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Spherical seed cores, spherical granules and process for production thereof

Also Published As

Publication number Publication date
HU9600575D0 (en) 1996-07-29
MX9600858A (es) 1997-06-28
FI961056A (fi) 1996-05-06
WO1996001621A1 (en) 1996-01-25
CA2170526A1 (en) 1996-01-25
RU2141822C1 (ru) 1999-11-27
CN1134108A (zh) 1996-10-23
BR9506026A (pt) 1997-10-14
SE9402422D0 (sv) 1994-07-08
HUT75772A (en) 1997-05-28
IL114448A (en) 1999-09-22
US5783215A (en) 1998-07-21
TW460300B (en) 2001-10-21
TR199500822A2 (tr) 1996-06-21
JPH09502738A (ja) 1997-03-18
IL114448A0 (en) 1995-11-27
PL313386A1 (en) 1996-06-24
ZA955545B (en) 1996-01-08
SK30396A3 (en) 1997-09-10
AU700949B2 (en) 1999-01-14
CZ73196A3 (en) 1996-08-14
AU2993695A (en) 1996-02-09
FI961056A0 (fi) 1996-03-07
EP0723434A1 (en) 1996-07-31
EE03280B1 (et) 2000-08-15
NZ289947A (en) 1998-07-28
NO960837D0 (no) 1996-02-29

Similar Documents

Publication Publication Date Title
NO960837L (no) Nye kuler for regulert frigjöring og et farmasöytisk preparat inneholdende slike
NO308660B1 (no) Nye 2,3-diketopiperazin-derivater eller deres salter, anvendelse derav og farmasøytisk preparat inneholdende slike
NO993484L (no) Farmasöytisk preparat med regulert frigjöringsvirkning
DE69023896D1 (de) Zementhilfsmittel, dessen herstellung sowie zementzusammensetzung.
NO172276C (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat med regulert frigjoering
NO954942L (no) Nye erytromycinderivater, fremgangsmåte for deres fremstilling og anvendelse av derivatene som legemidler
DE69003514D1 (de) Mit perforierungsvorsprüngen versehene näheinrichtung zum gebrauch in umformern zum verfertigen polsterkissenähnlichen materials, und verfahren hierzu.
MX9102255A (es) Tela revestida respirable, proceso y aparato para su produccion.
NO970036L (no) Nytt oralt, farmasöytisk preparat inneholdende magnesiumsalt av omeprazol
ES507236A0 (es) Un procedimiento para preparar una composicion farmaceutica para aplicacion topica, empleada en el tratamiento del acne.
BR8004420A (pt) Agente de cura para composicoes de laminacao de resina epoxi e composicao e artigo que usam o dito agente
EE03312B1 (et) Asendatud arüülalküültioalküültiopüridiinid Helicobacter bakterite tõrjeks, nende valmistamismeetod ja kasutamine ravimite valmistamiseks
NL176168B (nl) Werkwijze ter bereiding respectievelijk vervaardiging van een farmaceutisch preparaat en werkwijze ter bereiding van daarbij bruikbare nieuwe gesubstitueerde 1-(4-aminofenyl)-2-amino-ethanol-derivaten die, behalve een analgetische, uterusspasmolytische en anti-spastische werking op de dwarsgestreepte spieren, in het bijzonder een betaŸ2-mimetische en/of betaŸ1-blokkerende werking bezitten.
DK205083D0 (da) 4-aryl-4-piperidincarbinoler, estere, aminsalte og n-oxider deraf, deres fremstilling og anvendelse som laegemidler
EE03193B1 (et) (1-heteroasolüül-1-heterotsüklüül)alkaani derivaadid, nende saamise protsessid ja nende kasutamine närvisüsteemi kaitsvate vahendite valmistamiseks
DE69214364D1 (de) Photovernetzbare Harzzusammensetzung, holografisches Aufzeichnungsmaterial und holografisches Aufzeichnungsverfahren
DK656588A (da) Substituerede hydroxylaminer, deres fremstilling og anvendelse som laegemidler, samt ved fremstillingen anvendelige mellemprodukter og fremstilling deraf
NO306718B1 (no) Nye forbindelser med analgetisk og lokalanaestetisk effekt, farmasöytisk preparat inneholdende disse forbindelsene og deres anvendelse
NO940130D0 (no) Benzimidazolderivater, fremgangsmaate for deres fremstilling og te rapeutisk anvendelse derav
ITRM930286A0 (it) Composizione farmaceutica per somministrazione rettale nel trattamentodi cefaleo e relativo metodo di preparazione ed impiego.
IS3888A (is) Afleiður af cyclohexane og tetrahydropyran, aðferð til framleiðslu þeirra og notkunar sem lyfja
NO305862B1 (no) Nye (1-fenyl-1-heterocyklyl)alkanderivater, farmas°ytisk preparat og anvendelse av derivatene til fremstilling av neurobeskyttende midler
NO20031108L (no) Farmasöytisk preparat for behandling av hodepine, og fremgangsmåte for fremstilling av preparatet
NO930390L (no) Nye hetaryloxy-beta-carboliner, deres fremstilling og anvendelse i legemidler
IT1238356B (it) Derivati gangliosidici, loro uso quali agenti terapeutici, procedimento per la loro produzione e composti farmaceutici che li contengono.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application